Owens & Minor Reports Second Quarter 2022 Financial Results

Rhea-AI Summary

Owens & Minor reported Q2 2022 results with revenue of $2.5 billion and adjusted EBITDA of $156 million, reflecting a 145% increase in Patient Direct revenue. Despite success in its business segments, the company revised its full-year outlook with adjusted EPS projected between $2.85 and $3.15 due to weak hospital volumes and economic challenges. Key highlights include strong performance from the Byram business and successful integration of Apria, though macroeconomic headwinds and lower elective procedure volumes raised concerns about future growth.

Positive

• Q2 Patient Direct revenue of $573 million, up 145%
• Adjusted EBITDA increased by $28 million year-over-year, reaching $156 million
• Strong growth in Byram business revenue at 17%
• Successful integration synergies from Apria
• Generated $90 million in cash from operations during the quarter

Negative

• Adjusted EPS guidance revised down to $2.85-$3.15 due to weaker hospital volumes
• Lower hospital procedure volumes expected to remain below pre-pandemic levels
• Impact of $0.10 from foreign exchange on EPS guidance
• Macroeconomic headwinds affecting overall performance

Continued strength in Patient Direct with strong organic growth and acquisition synergies on track

Delivered Q2 adjusted EBITDA of $156 million

Weaker economic conditions and hospital volumes lead to new FY22 Adj. EPS outlook of $2.85-$3.15

RICHMOND, Va.--(BUSINESS WIRE)-- Owens & Minor, Inc. (NYSE-OMI) today reported financial results for the second quarter ended June 30, 2022, as summarized in the table below.

"I am very pleased with our performance in the second quarter, where the strength of our business model and the O&M business system helped us in the face of external conditions that continued to deteriorate over the quarter,” said Edward A. Pesicka, President and Chief Executive Officer.

"Our Patient Direct segment again executed very well and continues to grow as a percentage of total company profitability, and quarterly results were driven by the consistent strength in our Byram business that once again saw growth outpace the market. Apria also delivered a strong quarter and integration synergies are on track. We are strategically positioned very well to continue capitalizing on shifting preferences toward the home. In the Products & Healthcare Services segment, our differentiated, vertically integrated business model has enabled us to provide industry leading customer service levels as we continue to achieve high quality wins," Pesicka added.

"Looking to the balance of the year, we have considered the accelerating macroeconomic headwinds, as well as the unique labor and product availability challenges within acute care resulting in lower overall hospital volume. In recognition of these factors, we have revised our full year 2022 outlook. However, in our view, the economic landscape and industry-specific challenges will eventually improve, returning hospital procedure volumes to normalized levels. Because we have the right strategy and operating model, as well as a proven business system, I am confident in our ability to successfully manage through these challenges over time," Pesicka concluded.

Financial Summary(1)
($ in millions, except per share data)				2Q22				2Q21					YTD 2022					YTD 2021
Revenue				$2,500				$2,489					$4,907					$4,816
Operating income, GAAP				$75.1				$96.9					$136.1					$243.6
Adj. Operating Income, Non-GAAP				$113.6				$115.5					$218.5					$278.2
Net income, GAAP				$28.6				$65.9					$67.9					$135.5
Adj. Net Income, Non-GAAP				$58.3				$80.1					$131.0					$191.5
Adj. EBITDA, Non-GAAP				$155.6				$127.7					$274.1					$303.2
Net income per common share, GAAP				$0.37				$0.87					$0.89					$1.80
Adj. Net Income per share, Non-GAAP(2)				$0.76				$1.06					$1.72					$2.54

(1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below.
(2) Adjusted Net Income per share, Non-GAAP for Q2 2022 was unfavorably impacted as compared to prior year by foreign currency translation in the amount of $0.05 and $0.08 for the 2022 year-to-date period.

Q2 Results & Highlights

• Consolidated revenue of $2.5 billion
  • Patient Direct revenue of $573 million, up 145%, with Byram revenue growth of 17% and Apria pro forma up 4.4%
  • Products & Healthcare Services revenue of $1.9 billion, impacted by lower hospital procedure volume and the reduction of glove cost pass-through as expected
• Adjusted EBITDA of $156 million, up $28 million, with margin expansion of 110 basis to 6.2%
  • Strong first full quarter contribution from Apria
  • Productivity gains derived from the Owens & Minor business system
  • Partially offset by headwinds created by macroeconomic and industry-specific conditions, and
  • Unfavorable FX of $5 million
• Balance Sheet and Cash Flow
  • Generated $90 million of cash from operations in the quarter and $170 million year-to-date
  • Free cash flow (adjusted EBITDA less capital expenditures, net) of $107 million and $214 million year-to-date
  • Reduced total debt by $67 million
• Business Highlights
  • Received Premier Inc.’s 2022 Supplier Legacy Award in recognition of the value O&M provides to its members
  • Broke ground on West Virginia center of excellence for medical supply logistics
  • Hired Tammy Gomez as Executive Vice President and Chief Human Resources Officer
  • Elected Rita Johnson-Mills, Terri Kline and Carissa Rollins to our Board of Directors

Financial Outlook

The Company’s outlook for 2022 is subject to the key assumptions below:

• Revenue for 2022 to be in a range of $9.8 billion to $10.1 billion, reflecting:
  • Contribution in excess of $0.9 billion from Apria
  • Now expect elective procedures for the full year to be below pre-pandemic levels due to the slow start experienced in the first half of 2022
  • Continued expectation that PPE volumes will ease throughout the year

• Adjusted EBITDA for 2022 to be in a range of $570 million to $610 million, reflecting an increase related to Apria of approximately $180 million

• Adjusted EPS for 2022 to be in a range of $2.85 to $3.15, reflecting:
  • Higher inflation and interest rates
  • FX impact of $0.10, rates as of June 30, 2022

Investor Conference Call for Second Quarter 2022 Financial Results

Owens & Minor executives will host a conference call at 8:00 am. ET today, August 3, 2022, to discuss the results. The live webcast will be available on Owens & Minor’s Investor Relations website in the Events & Presentations section. Conference call participants are required to register in advance to obtain call-in information prior to the start of the call.

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This release contains certain ''forward-looking'' statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our expectations with respect to our 2022 financial performance, the Apria transaction, including related synergies and the expected performance of the Apria business, as well as statements related to the impact of COVID-19 on the Company’s results and operations and the Company’s expectations regarding the performance of its business including its ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s

Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC including the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.owens-minor.com. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio and an Americas-based manufacturing footprint for personal protective equipment (PPE) and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Owens & Minor, Inc.
Consolidated Statements of Operations (unaudited)
(dollars in thousands, except per share data)

	Three Months Ended June 30,
		2022				2021
Net revenue	$	2,500,015			$	2,489,460
Cost of goods sold		1,967,510				2,089,392
Gross margin		532,505				400,068
Distribution, selling and administrative expenses		452,813				294,096
Acquisition-related and exit and realignment charges		7,602				8,624
Other operating (income) expense, net		(2,995	)			464
Operating income		75,085				96,884
Interest expense, net		35,839				11,540
Other expense, net		783				1,028
Income before income taxes		38,463				84,316
Income tax provision		9,859				18,420
Net income	$	28,604			$	65,896
Net income per common share:
Basic	$	0.38			$	0.90
Diluted	$	0.37			$	0.87

Owens & Minor, Inc.
Consolidated Statements of Operations (unaudited)
(dollars in thousands, except per share data)

	Six Months Ended June 30,
		2022				2021
Net revenue	$	4,906,967			$	4,815,994
Cost of goods sold		4,001,014				3,973,175
Gross margin		905,953				842,819
Distribution, selling and administrative expenses		732,553				586,796
Acquisition-related and exit and realignment charges		41,150				14,587
Other operating income, net		(3,894	)			(2,141	)
Operating income		136,144				243,577
Interest expense, net		47,858				25,212
Loss on extinguishment of debt		—				40,433
Other expense, net		1,565				1,598
Income before income taxes		86,721				176,334
Income tax provision		18,837				40,848
Net income	$	67,884			$	135,486
Net income per common share:
Basic	$	0.92			$	1.87
Diluted	$	0.89			$	1.80

Owens & Minor, Inc.
Condensed Consolidated Balance Sheets (unaudited)
(dollars in thousands)

	June 30,			December 31,
		2022			2021
Assets
Current assets
Cash and cash equivalents	$	56,406		$	55,712
Accounts receivable, net of allowances of $14,922 and $18,003		743,853			681,564
Merchandise inventories		1,525,331			1,495,972
Other current assets		108,612			88,564
Total current assets		2,434,202			2,321,812
Property and equipment, net of accumulated depreciation of $373,954 and $334,500		595,888			317,235
Operating lease assets		278,291			194,006
Goodwill		1,656,308			390,185
Intangible assets, net		462,444			209,745
Other assets, net		128,145			103,568
Total assets	$	5,555,278		$	3,536,551
Liabilities and equity
Current liabilities
Accounts payable	$	1,137,337		$	1,001,959
Accrued payroll and related liabilities		97,829			115,858
Other current liabilities		334,198			226,204
Total current liabilities		1,569,364			1,344,021
Long-term debt, excluding current portion		2,565,613			947,540
Operating lease liabilities, excluding current portion		220,504			162,241
Deferred income taxes		107,181			35,310
Other liabilities		133,957			108,938
Total liabilities		4,596,619			2,598,050
Total equity		958,659			938,501
Total liabilities and equity	$	5,555,278		$	3,536,551

Owens & Minor, Inc.
Consolidated Statements of Cash Flows (unaudited)
(dollars in thousands)

	Six Months Ended June 30,
(in thousands)		2022				2021
Operating activities:
Net income	$	67,884			$	135,486
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization		97,286				45,501
Share-based compensation expense		11,210				13,040
Loss on extinguishment of debt		—				40,433
Provision for losses on accounts receivable		4,512				15,777
Deferred income tax expense (benefit)		1,601				(11,293	)
Changes in operating lease right-of-use assets and lease liabilities		606				826
Loss on sale and dispositions of property and equipment		226				—
Changes in operating assets and liabilities:
Accounts receivable		16,275				(57,256	)
Merchandise inventories		(24,438	)			(298,294	)
Accounts payable		12,349				127,473
Net change in other assets and liabilities		(23,945	)			(3,363	)
Other, net		5,958				4,076
Cash provided by operating activities		169,524				12,406
Investing activities:
Acquisition, net of cash acquired		(1,684,607	)			—
Additions to property and equipment		(62,236	)			(14,630	)
Additions to computer software		(3,463	)			(4,051	)
Proceeds from sale of property and equipment		5,846				22
Other, net		(839	)			—
Cash used for investing activities		(1,745,299	)			(18,659	)
Financing activities:
Proceeds from issuance of debt		1,691,000				500,000
Borrowings under revolving credit facility, net and accounts receivable securitization program		30,000				5,000
Repayments of debt		(1,500	)			(523,140	)
Borrowings under amended accounts receivable securitization program		347,800				—
Repayments under amended accounts receivable securitization program		(402,800	)			—
Financing costs paid		(41,479	)			(12,868	)
Cash dividends paid		—				(364	)
Payment for termination of interest rate swaps		—				(15,434	)
Other, net		(42,388	)			(17,982	)
Cash provided by (used for) financing activities		1,580,633				(64,788	)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(3,864	)			(1,718	)
Net increase (decrease) in cash, cash equivalents and restricted cash		994				(72,759	)
Cash, cash equivalents and restricted cash at beginning of period		72,035				134,506
Cash, cash equivalents and restricted cash at end of period (1)	$	73,029			$	61,747
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	$	25,782			$	68,030
Interest paid	$	32,417			$	17,768
Noncash investing activity:
Unpaid purchases of property and equipment at end of period	$	56,429			$	—

⁽¹⁾ Restricted cash included in Other assets, net as of June 30, 2022 and December 31, 2021 primarily represents cash held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) initiatives related to wind-down costs of Fusion5.

Owens & Minor, Inc.
Summary Segment Information (unaudited)
(dollars in thousands)

	Three Months Ended June 30,
	2022							2021
					% of							% of
					consolidated							consolidated
	Amount				net revenue			Amount				net revenue
Net revenue:
Products & Healthcare Services	$	1,927,388			77.10	%		$	2,255,820			90.61	%
Patient Direct		572,627			22.90	%			233,640			9.39	%
Consolidated net revenue	$	2,500,015			100.00	%		$	2,489,460			100.00	%
					% of segment							% of segment
Operating income:					net revenue							net revenue
Products & Healthcare Services	$	61,243			3.18	%		$	101,229			4.49	%
Patient Direct		52,332			9.14	%			14,305			6.12	%
Intangible amortization		(30,888	)						(10,026	)
Acquisition-related and exit and realignment charges		(7,602	)						(8,624	)
Consolidated operating income	$	75,085			3.00	%		$	96,884			3.89	%
Depreciation and amortization:
Products & Healthcare Services	$	19,209						$	18,847
Patient Direct		53,952							3,753
Consolidated depreciation and amortization	$	73,161						$	22,600
Capital expenditures:
Products & Healthcare Services	$	18,418						$	11,806
Patient Direct		36,320							252
Consolidated capital expenditures	$	54,738						$	12,058

Owens & Minor, Inc.
Summary Segment Information (unaudited)
(dollars in thousands)

	Six Months Ended June 30,
	2022							2021
					% of							% of
					consolidated							consolidated
	Amount				net revenue			Amount				net revenue
Net revenue:
Products & Healthcare Services	$	4,061,429			82.77	%		$	4,365,265			90.64	%
Patient Direct		845,538			17.23	%			450,729			9.36	%
Consolidated net revenue	$	4,906,967			100.00	%		$	4,815,994			100.00	%
					% of segment							% of segment
Operating income:					net revenue							net revenue
Products & Healthcare Services	$	150,325			3.70	%		$	251,647			5.76	%
Patient Direct		68,125			8.06	%			26,569			5.89	%
Intangible amortization		(41,156	)						(20,052	)
Acquisition-related and exit and realignment charges		(41,150	)						(14,587	)
Consolidated operating income	$	136,144			2.77	%		$	243,577			5.06	%
Depreciation and amortization:
Products & Healthcare Services	$	38,203						$	38,007
Patient Direct		59,083							7,494
Consolidated depreciation and amortization	$	97,286						$	45,501
Capital expenditures:
Products & Healthcare Services	$	29,061						$	18,270
Patient Direct		36,638							411
Consolidated capital expenditures	$	65,699						$	18,681

Owens & Minor, Inc.
Net Income per Common Share (unaudited)
(dollars in thousands, except per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
		2022			2021			2022			2021
Net income	$	28,604		$	65,896		$	67,884		$	135,486
Weighted average shares outstanding - basic		74,710			72,818			74,158			72,474
Dilutive shares		1,587			2,987			2,011			2,791
Weighted average shares outstanding - diluted		76,297			75,805			76,169			75,265
Net income per common share:
Basic	$	0.38		$	0.90		$	0.92		$	1.87
Diluted	$	0.37		$	0.87		$	0.89		$	1.80

Owens & Minor, Inc.
GAAP/Non-GAAP Reconciliations (unaudited)
(dollars in thousands, except per share data)

The following table provides a reconciliation of reported operating income, net income and net income per share to non-GAAP measures used by management.

		Three Months Ended June 30,								Six Months Ended June 30,
			2022				2021				2022				2021
Operating income, as reported (GAAP)		$	75,085			$	96,884			$	136,144			$	243,577
Intangible amortization (1)			30,888				10,026				41,156				20,052
Acquisition-related and exit and realignment charges(2)			7,602				8,624				41,150				14,587
Operating income, adjusted (non-GAAP) (Adjusted Operating Income)		$	113,575			$	115,534			$	218,450			$	278,216
Operating income as a percent of net revenue (GAAP)			3.00	%			3.89	%			2.77	%			5.06	%
Adjusted operating income as a percent of net revenue (non-GAAP)			4.54	%			4.64	%			4.45	%			5.78	%
Net income, as reported (GAAP)		$	28,604			$	65,896			$	67,884			$	135,486
Intangible amortization (1)			30,888				10,026				41,156				20,052
Income tax benefit (5)			(7,408	)			(2,411	)			(9,986	)			(5,197	)
Acquisition-related and exit and realignment charges(2)			7,602				8,624				41,150				14,587
Income tax benefit (5)			(1,823	)			(2,073	)			(9,985	)			(3,780	)
Loss on extinguishment of debt (3)			—				—				—				40,433
Income tax benefit (5)			—				—				—				(10,477	)
Other (4)			525				570				1,049				1,140
Income tax benefit (5)			(127	)			(137	)			(254	)			(295	)
Tax adjustment (7)			—				(402	)			—				(402	)
Net income, adjusted (non-GAAP) (Adjusted Net Income)		$	58,261			$	80,093			$	131,014			$	191,547
Net income per diluted common share, as reported (GAAP)		$	0.37			$	0.87			$	0.89			$	1.80
Intangible amortization (1)			0.30				0.10				0.41				0.20
Acquisition-related and exit and realignment charges(2)			0.08				0.09				0.41				0.14
Loss on extinguishment of debt (3)			—				—				—				0.40
Other (4)			0.01				0.01				0.01				0.01
Tax adjustment (7)			—				(0.01	)			—				(0.01	)
Net income per diluted common share, adjusted (non-GAAP) (Adjusted EPS)		$	0.76			$	1.06			$	1.72			$	2.54

Owens & Minor, Inc.
GAAP/Non-GAAP Reconciliations (unaudited), continued
(dollars in thousands)

The following tables provide reconciliations of net income and total debt to non-GAAP measures used by management.

		Three Months Ended June 30,						Six Months Ended June 30,						Trailing Twelve Months Ended June 30, 2022
			2022			2021			2022			2021
Net income, as reported (GAAP)		$	28,604		$	65,896		$	67,884		$	135,486		$	153,988
Income tax provision			9,859			18,420			18,837			40,848			33,154
Interest expense, net			35,839			11,540			47,858			25,212			70,736
Intangible amortization (1)			30,888			10,026			41,156			20,052			60,912
Other depreciation and amortization (6)			42,273			12,575			56,131			25,448			81,494
EBITDA (non-GAAP)		$	147,463		$	118,457		$	231,866		$	247,046		$	400,284
Acquisition-related and exit and realignment charges (2)			7,602			8,624			41,150			14,587			60,639
Loss on extinguishment of debt (3)			—			—			—			40,433			—
Other (4)			525			570			1,049			1,140			2,188
EBITDA, adjusted (non-GAAP) (Adjusted EBITDA)		$	155,590		$	127,651		$	274,065		$	303,206		$	463,111

		Three Months Ended June 30, 2022				Six Months Ended June 30, 2022
EBITDA, adjusted (non-GAAP) (Adjusted EBITDA)		$	155,590			$	274,065
Capital expenditures, net (8)			(48,666	)			(59,627	)
Free Cash Flow (non-GAAP)		$	106,924			$	214,438

		June 30,
			2022
Total debt, as reported (GAAP)		$	2,576,428
Cash and cash equivalents			56,406
Net debt (non-GAAP)		$	2,520,022

Owens & Minor, Inc.

GAAP/Non-GAAP Reconciliations (unaudited), continued

The following items have been excluded in our non-GAAP financial measures:

⁽¹⁾ Intangible amortization includes amortization of intangible assets established during purchase accounting for business combinations. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results and the results of our peers.

⁽²⁾ Acquisition-related charges were $6.4 million and $38.3 million for the three and six months ended June 30, 2022 as compared to no acquisition-related charges for the three and six months ended June 30, 2021. Acquisition-related costs in 2022 consisted primarily of costs related to the Apria acquisition. Acquisition-related charges for the twelve months ended June 30, 2022 were $41.4 million and consisted primarily of costs related to the Apria acquisition. Exit and realignment charges were $1.2 million and $2.9 million for the three and six months ended June 30, 2022 and consisted primarily of severance and other charges associated with the reorganization of our segments. Exit and realignment charges were $8.6 million and $14.6 million for the three and six months ended June 30, 2021 and consisted primarily of an increase in reserves associated with certain retained assets of Fusion5, IT restructuring charges and other costs related to the reorganization of our U.S. operations. Exit and realignment charges for the twelve months ended June 30, 2022 were $19.2 million and consisted of costs associated with our strategic organizational realignment, wind-down costs related to Fusion5, IT restructuring charges and other items.

⁽³⁾ Loss on extinguishment of debt for the six months ended June 30, 2021 includes the write-off of deferred financing costs and third party fees associated with the debt financing in March 2021 of $15.3 million and amounts reclassified from accumulated other comprehensive loss as a result of the termination of our interest rate swaps of $25.1 million.

⁽⁴⁾ Other includes interest costs and net actuarial losses related to our retirement plans for the three and six months ended June 30, 2022 and 2021, as well as the twelve months ended June 30, 2022.

⁽⁵⁾ These charges have been tax effected in the preceding table by determining the income tax rate depending on the amount of charges incurred in different tax jurisdictions and the deductibility of those charges for income tax purposes.

⁽⁶⁾ Other depreciation and amortization includes depreciation expense for property and equipment and amortization for capitalized computer software.

⁽⁷⁾ Includes tax adjustments associated with the estimated benefits under the Tax Cuts and Jobs Act and the Coronavirus Aid, Relief, and Economic Security (CARES) Act.

⁽⁸⁾ Capital expenditures, net is defined as capital expenditures less the net book value of dispositions of property and equipment during the accounting period.

Use of Non-GAAP Measures

This earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). In general, the measures exclude items and charges that (i) management does not believe reflect Owens & Minor, Inc.'s (the "Company") core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends. Management uses these non-GAAP financial measures internally to evaluate the Company's performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.

Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005240/en/

Alex Jost, CPA

Director, Investor Relations

Investor.Relations@owens-minor.com

Source: Owens & Minor, Inc.

FAQ

What were Owens & Minor's Q2 2022 revenue and adjusted EBITDA figures?

Owens & Minor reported Q2 2022 revenue of $2.5 billion and adjusted EBITDA of $156 million.

How has the economic downturn affected Owens & Minor's outlook for 2022?

The company revised its FY22 adjusted EPS outlook to between $2.85 and $3.15 due to weaker hospital volumes.

What factors contributed to the strong growth in Owens & Minor's Patient Direct segment?

Patient Direct revenue increased by 145%, driven by growth in the Byram business and successful integration of Apria.

What were the cash flow results for Owens & Minor in Q2 2022?

The company generated $90 million in cash from operations for Q2 2022.

What is the expected revenue range for Owens & Minor in 2022?

Owens & Minor's revenue for 2022 is expected to be between $9.8 billion and $10.1 billion.